Thyroid cancer is a common type of endocrine malignancy, and its incidence has been
steadily increasing in many regions of the world. Initiation and progression of thyroid cancer …

Substantial developments have occurred in the past 5–10 years in clinical translational
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …

Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of
papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter …

Importance BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its
role in PTC-related patient mortality has not been established. Objective To investigate the …

Clinicians have long sought to characterize biological markers of neoplasia as objective
indicators of tumor presence, pathogenicity, and prognosis. Armed with data that correlate …

Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-
specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive …

Background: There is conflicting literature regarding the association of the BRAF V600E
mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC) …

Introduction Over the past years, the incidence of thyroid cancer has surged not only in
Germany but also in other countries of the Western hemisphere. This surge was first and …

Background Mutation of BRAF is a predominant event in cancers with poor prognosis such
as melanoma and colorectal cancer. BRAF mutation leads to a constitutive activation of …

This study investigated the sensitivity and specificity of immunohistochemical (IHC) analysis
using an anti-BRAF antibody to detect the presence of the BRAF V600E mutation in patients …